Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

Digital Engagement for Lifelong Health (DELPHI)

25 maggio 2026 aggiornato da: Gennaro Tartarisco, Istituto per la Ricerca e l'Innovazione Biomedica

Digital Engagement for Lifelong Prevention and Health Improvement

The DELPHI project (Digital Engagement for Lifelong Prevention and Health Improvement) aims to develop, implement, and validate an advanced digital platform for promoting well-being and personalized prevention of chronic non-communicable diseases in healthy adults. By integrating wearable sensors, artificial intelligence, federated learning, and the Human Digital Twin (HDT) paradigm, the DELPHI platform is designed to collect, analyze, and interpret multidimensional data in order to deliver dynamic and personalized recommendations for healthy lifestyles.

The study adopts a multicenter, randomized controlled pilot design, with a maximum duration of 12 months per participant. A total of 200 healthy adults aged 18-65 will be recruited in Southern Italy (Sicily, Campania, and Basilicata) and randomly assigned to either: (1) an experimental group using the full DELPHI platform, including personalized recommendations, adaptive content, and continuous feedback; or (2) a control group using a basic version limited to passive monitoring.

As a non-clinical primary prevention pilot study, DELPHI aims to assess the operational feasibility, usability, and acceptability of the platform in real-world settings, while also exploring preliminary signals of impact on health and lifestyle domains without confirmatory purposes. Secondary objectives include monitoring physiological indicators, adherence to the app and wearable devices, and evaluating the feasibility of implementing the platform in workplace environments.

Data collection will rely on wearable devices, digital questionnaires, and behavioral analysis, with strong safeguards for personal data protection in compliance with GDPR and advanced security approaches such as federated learning and encryption.

Specific subgroups, including workers from the Fondazione Don Carlo Gnocchi (FDG) as well as university staff and students, will be involved in targeted assessments related to mental well-being and distress. In addition, workers from the FDG will test a virtual reality module designed to evaluate biomechanical overload risks during manual handling activities in simulated environments. These additional physiological and virtual reality components are exploratory and non-diagnostic.

Overall, DELPHI seeks to provide a solid foundation for the adoption of predictive and personalized models in digital health, contributing to the development of a sustainable and accessible prevention ecosystem, particularly in Southern Italy.

Panoramica dello studio

Stato

Reclutamento

Condizioni

Intervento / Trattamento

Tipo di studio

Interventistico

Iscrizione (Stimato)

200

Fase

  • Non applicabile

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Contatto studio

Backup dei contatti dello studio

Luoghi di studio

  • Italia
      • Messina, Italia, 98164
        • Reclutamento
        • Institute for Biomedical Research and Innovation (IRIB)-National Reasearch Council (CNR)
        • Sub-investigatore:
          • Roberta Bruschetta
        • Sub-investigatore:
          • Simona Campisi
        • Sub-investigatore:
          • Maria Valeria Maiorana
        • Investigatore principale:
          • Gennaro Tartarisco
        • Sub-investigatore:
          • Serena Iacono Isidoro
        • Sub-investigatore:
          • Concetta Polizzi
        • Sub-investigatore:
          • Renato Tino
        • Sub-investigatore:
          • Marco Germanotta
        • Contatto:
        • Sub-investigatore:
          • Irene Aprile
        • Sub-investigatore:
          • Mariacristina Siotto
        • Sub-investigatore:
          • Alessandro Guerrini
        • Sub-investigatore:
          • Monia Andrea Papa
        • Sub-investigatore:
          • Giorgia Bruschetta
        • Sub-investigatore:
          • Barbara Caci
        • Sub-investigatore:
          • Maria Cocchiara
        • Sub-investigatore:
          • Flavia Altavilla
        • Sub-investigatore:
          • Alessia Valdesi
        • Sub-investigatore:
          • Chiara Urone
        • Sub-investigatore:
          • Giulia Giordano

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

  • Adulto
  • Adulto più anziano

Accetta volontari sani

Sì

Descrizione

Inclusion Criteria:

  • Apparent good general health status, confirmed by medical history and initial self-assessment.
  • Ability to understand the study information and provide informed consent.
  • Availability and motivation to participate for the entire duration of the study (12 months).
  • Access to a smartphone compatible with the DELPHI application.
  • Willingness to wear the wearable devices for continuous monitoring of physiological parameters.
  • Basic familiarity with mobile applications or willingness to receive training on their use.
  • Signed informed consent.

Exclusion Criteria:

  • Presence of severe chronic diseases in active phase (e.g., oncological, cardiovascular, or neurological diseases).
  • Acute or unstable conditions that could compromise participation in the protocol.
  • Current pregnancy.
  • Diagnosed major cognitive or psychiatric disorders that hinder understanding of or adherence to the protocol.
  • Current use of medications that significantly affect the parameters being monitored (e.g., psychotropic drugs, beta-blockers).
  • Simultaneous participation in other clinical studies.
  • Logistical difficulties that prevent frequent interaction with the platform (e.g., lack of connection, unwillingness to attend periodic follow-ups).

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Scopo principale: Prevenzione
  • Assegnazione: Randomizzato
  • Modello interventistico: Assegnazione parallela
  • Mascheramento: Nessuno (etichetta aperta)

Armi e interventi

Gruppo di partecipanti / Arm
Intervento / Trattamento
Sperimentale: Experimental group
Participants will use the full version of the DELPHI platform, including wearable sensors, mobile app-based data collection, personalized recommendations generated through artificial intelligence algorithms, multimedia content (physical exercises, mindfulness activities, and educational videos), as well as interactive notifications and feedback.
Altro: DELPHI Personalized Digital Prevention Platform

the full version of the DELPHI digital platform, designed to support personalized primary prevention and health promotion. The intervention includes continuous monitoring through wearable sensors (Fitbit Inspire 3), mobile app-based data collection, and adaptive lifestyle recommendations generated by artificial intelligence algorithms within a Human Digital Twin framework.

Participants will receive personalized feedback and notifications related to physical activity, sleep, nutrition, hydration, stress management, and psychological well-being. The platform also delivers multimedia educational content, including guided exercises, mindfulness and breathing practices, wellness educational videos, and behavioral micro-actions. Data collected through wearable devices, digital questionnaires, and behavioral monitoring are used to dynamically tailor recommendations and preventive strategies throughout the study period.
Altro: Control group
Participants will access a limited version of the application restricted to passive monitoring functions only, without personalized recommendations, adaptive content, or interactive notifications.
Altro: Passive Digital Monitoring Control

Participants assigned to the control group will use a limited version of the DELPHI application restricted to passive monitoring functions. The application will collect data from wearable devices and questionnaires related to physical activity, sleep, nutrition, and well-being, but participants will not receive personalized recommendations, adaptive educational content, interactive feedback, or behavioral notifications.

The control condition is intended to provide observational digital monitoring only, without active preventive intervention or AI-based personalization.

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
World Health Organization Quality of Life (WHOQoL)
Lasso di tempo: Baseline and 6 months
The World Health Organization Quality of Life (WHOQoL) is a questionnaire used to assess quality of life.The WHOQOL-BREF, its short form, includes 26 items and evaluates four domains: physical health, psychological health, social relationships, and environment. It does not generate a single total score; instead, it provides separate domain scores, with higher values indicating better quality of life
Baseline and 6 months
Depression, Anxiety, and Stress Symptoms (DASS-21)
Lasso di tempo: Baseline and 6 months

The Depression, Anxiety and Stress Scales-21 (DASS-21) is a 21-item self-report instrument designed to assess the severity of depression, anxiety, and stress symptoms. It consists of three subscales, each containing 7 items, and uses a 4-point response format. The scale provides separate scores for depression, anxiety, and stress rather than a single diagnostic score.

  • Depression: normal 0-9, mild 10-13, moderate 14-20, severe 21-27, extremely severe 28+.
  • Anxiety: normal 0-7, mild 8-9, moderate 10-14, severe 15-19, extremely severe 20+.
  • Stress: normal 0-14, mild 15-18, moderate 19-25, severe 26-33, extremely severe 34+.
Baseline and 6 months
Beck Depression Inventory-II (BDI-II)
Lasso di tempo: Baseline and 6 months

The Beck Depression Inventory-II (BDI-II) is a 21-item self-report instrument designed to measure the severity of depressive symptoms over the past two weeks. Each item is rated on a 0 to 3 scale, and the total score ranges from 0 to 63.

The total BDI-II score is calculated by summing all 21 items, giving a range from 0 to 63. Common interpretive cut-offs are: minimal depression 0-13, mild 14-19, moderate 20-28, and severe 29-63
Baseline and 6 months
International Physical Activity Levels (IPAQ)
Lasso di tempo: Baseline and 6 months

The International Physical Activity Questionnaire (IPAQ) is a self-report instrument designed to assess physical activity levels over the previous 7 days. It provides both a categorical score, classifying individuals as low, moderate, or high active, and a continuous score expressed as MET-minutes per week.

  • Categorical score: low, moderate, or high physical activity.
  • Continuous score: total physical activity expressed as MET-minutes/week.

The continuous score is calculated using standard MET values:

  • Walking = 3.3 METs.
  • Moderate activity = 4.0 METs.
  • Vigorous activity = 8.0 METs.
Baseline and 6 months
Prevention with Mediterranean Diet (PREDIMED)
Lasso di tempo: Baseline and 6 months
The Prevention with Mediterranean Diet (PREDIMED) questionnaire is a 14-item tool designed to assess adherence to the Mediterranean diet. Each item is scored as 0 or 1, and the total score ranges from 0 to 14, with higher scores indicating greater adherence to the Mediterranean dietary pattern.
Baseline and 6 months

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Heart Rate
Lasso di tempo: Continuously monitored from baseline to 6 months
Average heart rate measured through wearable sensors in beats per minute (bpm). Normal resting heart rate in adults is commonly about 60 to 100 bpm
Continuously monitored from baseline to 6 months
Heart Rate Variability (HRV)
Lasso di tempo: Continuously monitored from baseline to 6 months
Nocturnal heart rate variability measured in milliseconds using wearable sensors.
Continuously monitored from baseline to 6 months
Body Weight
Lasso di tempo: Baseline, every 2 weeks during the 6-month intervention period and 6 months
Change in body weight measured in kilograms (kg).
Baseline, every 2 weeks during the 6-month intervention period and 6 months
Body Mass Index (BMI)
Lasso di tempo: Baseline and 6 months
adults, BMI is usually interpreted as follows: Underweight: below 18.5 Healthy weight: 18.5 to 24.9 Overweight: 25.0 to 29.9 Obesity: 30.0 or above
Baseline and 6 months
Nutritional Intake
Lasso di tempo: Weekly monitoring from baseline to 6 months
Daily caloric, macronutrient, and micronutrient intake measured through in-app food diary records.
Weekly monitoring from baseline to 6 months
Mental Well-Being Weekly Check-in Scores
Lasso di tempo: Weekly from baseline to 6 months
Weekly emotional well-being indicators measured through a 6-item Likert-scale in-app questionnaire assessing mood, calmness, energy, tension, and distress.
Weekly from baseline to 6 months

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Sponsor

Istituto per la Ricerca e l'Innovazione Biomedica

Collaboratori

Fondazione Don Carlo Gnocchi Onlus
Universita degli Studi di Palermo
Medilink s.r.l.

Investigatori

  • Investigatore principale: Gennaro Tartarisco, Institute for Biomedical Research and Innovation (IRIB)-National Reasearch Council (CNR)

Pubblicazioni e link utili

La persona responsabile dell'inserimento delle informazioni sullo studio fornisce volontariamente queste pubblicazioni. Questi possono riguardare qualsiasi cosa relativa allo studio.

Pubblicazioni generali

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Effettivo)

4 maggio 2026

Completamento primario (Stimato)

30 novembre 2026

Completamento dello studio (Stimato)

30 marzo 2027

Date di iscrizione allo studio

Primo inviato

19 maggio 2026

Primo inviato che soddisfa i criteri di controllo qualità

25 maggio 2026

Primo Inserito (Effettivo)

29 maggio 2026

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

29 maggio 2026

Ultimo aggiornamento inviato che soddisfa i criteri QC

25 maggio 2026

Ultimo verificato

1 maggio 2026

Maggiori informazioni

Termini relativi a questo studio

Parole chiave

Termini MeSH pertinenti aggiuntivi

Altri numeri di identificazione dello studio

  • CNR-IRIB-PRO-2026-004

Piano per i dati dei singoli partecipanti (IPD)

Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?

NO

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

No

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

No

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .

Prove cliniche su La promozione della salute

Prove cliniche su DELPHI Personalized Digital Prevention Platform

Cerca prove simili

Sponsor e collaboratori

Condizioni mediche

Interventi farmacologici

CROs by country

CROs in Cote d'Ivoire

Condizioni

Malattie rare

Interventi farmacologici

Supplementi dietetici

Sponsor / Collaboratori

Sedi

Sottoscrivi